Karen House

990 total citations
19 papers, 830 citations indexed

About

Karen House is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Animal Science and Zoology. According to data from OpenAlex, Karen House has authored 19 papers receiving a total of 830 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Physiology, 13 papers in Pulmonary and Respiratory Medicine and 3 papers in Animal Science and Zoology. Recurrent topics in Karen House's work include Asthma and respiratory diseases (14 papers), Inhalation and Respiratory Drug Delivery (12 papers) and Respiratory and Cough-Related Research (9 papers). Karen House is often cited by papers focused on Asthma and respiratory diseases (14 papers), Inhalation and Respiratory Drug Delivery (12 papers) and Respiratory and Cough-Related Research (9 papers). Karen House collaborates with scholars based in United States, United Kingdom and Sweden. Karen House's co-authors include Leslie Baitinger, Tushar Shah, Barbara A. Prillaman, Craig LaForce, Paul Dorinsky, Martha V. White, Gary N. Gross, Mani S. Kavuru, Julian Melamed and Gail Shapiro and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Respiratory and Critical Care Medicine and Cancer.

In The Last Decade

Karen House

17 papers receiving 777 citations

Peers

Karen House

PHYSI

PRM

PPCH

SURGE

G Todd United Kingdom

Kenneth M. Kral United States

A. Manon Brenner United States

G. Balzano Italy

Montserrat Torrejón Spain

Anahí Yáñez Argentina

Frank L. Custers Netherlands

P. Mowinckel Norway

Iain Small United Kingdom

Luís Pérez de Llano Spain

G Todd United Kingdom

Karen House

322 ×0.4

PHYSI

298 ×0.4

PRM

46 ×0.6

PPCH

23 ×0.4

SURGE

28 ×0.5

Citations per year, relative to Karen House Karen House (= 1×) peers G Todd

Countries citing papers authored by Karen House

Since Specialization

Citations

This map shows the geographic impact of Karen House's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen House with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen House more than expected).

Fields of papers citing papers by Karen House

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen House. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen House. The network helps show where Karen House may publish in the future.

Co-authorship network of co-authors of Karen House

This figure shows the co-authorship network connecting the top 25 collaborators of Karen House. A scholar is included among the top collaborators of Karen House based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen House. Karen House is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Bleecker, Eugene R., Eric D. Bateman, Ashley Woodcock, et al.. (2012). Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Annals of Allergy Asthma & Immunology. 109(5). 353–358.e4. 45 indexed citations

Pan, Minggui, et al.. (2012). Impact of early engagement of patients with clinical trial information in a system-based multidisciplinary breast cancer clinic on clinical trial enrollment.. Journal of Clinical Oncology. 30(34_suppl). 149–149. 2 indexed citations

Daley‐Yates, Peter T., et al.. (2009). Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 μg and fluticasone propionate 250 μg: Implications for establishing bioequivalence of inhaled products. Clinical Therapeutics. 31(2). 370–385. 37 indexed citations

Daley‐Yates, Peter T., et al.. (2009). . Clinical Therapeutics. 31(8). 1882–1884.

Daley‐Yates, Peter T., et al.. (2009). . Clinical Therapeutics. 31(12). 3022–3024.

Cowie, Robert, Louis‐Philippe Boulet, Paul K. Keith, et al.. (2007). Tolerability of a Salmeterol Xinafoate/Fluticasone Propionate Hydrofluoroalkane Metered-Dose Inhaler in Adolescent and Adult Patients with Persistent Asthma: A 52-Week, Open-Label, Stratified, Parallel-Group, Multicenter Study. Clinical Therapeutics. 29(7). 1390–1402. 9 indexed citations

Nathan, Robert A., Anthony R. Rooklin, Catherine A. Scott, et al.. (2006). Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. Clinical Therapeutics. 28(1). 73–85. 39 indexed citations

LaForce, Craig, et al.. (2005). The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Annals of Allergy Asthma & Immunology. 95(1). 66–71. 51 indexed citations

House, Karen, et al.. (2004). The Safety of Fluticasone propionate/Salmeterol Diskus® in Pediatric Patients Ages 4 –11 with Asthma. CHEST Journal. 126(4). 911S–911S. 8 indexed citations

10.

Murray, John, Richard R. Rosenthal, Laura L. Somerville, et al.. (2004). Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting β2-agonists. Annals of Allergy Asthma & Immunology. 93(4). 351–359. 34 indexed citations

11.

Pearlman, David S., David B. Peden, John J. Condemi, et al.. (2004). Efficacy and Safety of Fluticasone Propionate/Salmeterol HFA 134A MDI in Patients with Mild‐to‐Moderate Persistent Asthma. Journal of Asthma. 41(8). 797–806. 40 indexed citations

12.

Rosenthal, Richard R., et al.. (2002). Fluticasone propionate/salmeterol Diskus® combination product provides superior asthma control compared with fluticasone propionate and salmeterol alone in patients previously receiving PRN short-acting beta2-agonists alone. Journal of Allergy and Clinical Immunology. 109(1). S245–S245. 4 indexed citations

13.

Edin, Heather M., et al.. (2002). Fluticasone propionate/salmeterol diskus combination product improves asthma-related quality of life compared with individual components in asthma patients symptomatic on β2 agonists alone. Journal of Allergy and Clinical Immunology. 109(1). S241–S241. 4 indexed citations

14.

Shapiro, Gail, William R. Lumry, James Wolfe, et al.. (2000). Combined Salmeterol 50 μ g and Fluticasone Propionate 250 μ g in the Diskus Device for the Treatment of Asthma. American Journal of Respiratory and Critical Care Medicine. 161(2). 527–534. 176 indexed citations

15.

Kavuru, Mani S., Julian Melamed, Gary N. Gross, et al.. (2000). Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled trial. Journal of Allergy and Clinical Immunology. 105(6). 1108–1116. 199 indexed citations

16.

LaForce, Craig, David S. Pearlman, Michael E. Ruff, et al.. (2000). Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma. Annals of Allergy Asthma & Immunology. 85(5). 407–415. 48 indexed citations

17.

Peden, David B., et al.. (1998). Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma. Journal of Allergy and Clinical Immunology. 102(1). 32–38. 72 indexed citations

18.

Sledge, George W., et al.. (1992). Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer. 70(10). 2524–2528. 47 indexed citations

19.

Berry, William L., et al.. (1992). Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy.. PubMed. 19(6 Suppl 15). 33–7. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact